Dataset Information

Tenuigenin attenuates ?-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3.

ABSTRACT:

Background and aims

Tenuigenin (Ten) is a Chinese herbal extract with antioxidative and antiinflammatory effects on toxin-induced cell models of Parkinson's disease (PD); however, its effects on ?-synuclein toxicity-based PD models remain unknown. ?-synuclein hyperphosphorylation is a key event in PD pathogenesis and potential target of therapeutic interventions. We tested whether Ten alleviates ?-synuclein-induced cytotoxicity via reducing kinases that phosphorylate ?-synuclein.

Methods

SH-SY5Y cells transiently transfected with wild-type or A53T mutant ?-synuclein were used to evaluate the effect of Ten on the levels of ?-synuclein phosphorylation-related kinases. Cells treated with 10 ?M Ten for 24 h were measured for viability (proliferation and apoptosis assays) and cellular proteins harvested and fractioned. The levels of total and phosphorylated ?-synuclein and five associated kinases (polo-like kinase [PLK] 1-3, casein kinase [CK] 1-2) were evaluated by Western blotting.

Results

Overexpression of either wild-type or A53T mutant ?-synuclein decreased cell viability and increased ?-synuclein phosphorylation. Ten treatment-protected cells from this ?-synuclein-induced toxicity and dramatically reduced ?-synuclein phosphorylation and PLK3 (but not other kinase) levels.

Conclusion

In ?-synuclein cell model of PD, Ten is effective in attenuating ?-synuclein-induced toxicity and ?-synuclein phosphorylation probably via targeting PLK3, suggesting it could be an efficient therapeutic drug to treat ?-synuclein-related neurodegeneration.

SUBMITTER: Zhou JX

PROVIDER: S-EPMC6493467 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Tenuigenin attenuates α-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3.

Zhou Jin-Xia JX Zhang Hao-Bo HB Huang Yue Y He Yi Y Zheng Yan Y Anderson John P JP Gai Wei-Ping WP Liang Zhi-Gang ZG Wang Yong Y Ren Xin-Miao XM Wang Qi Q Gong Xiao-Li XL Yang Jian J Wang Xuan X Halliday Glenda G Wang Xiao-Min XM

CNS neuroscience & therapeutics 20130527 9

<h4>Background and aims</h4>Tenuigenin (Ten) is a Chinese herbal extract with antioxidative and antiinflammatory effects on toxin-induced cell models of Parkinson's disease (PD); however, its effects on α-synuclein toxicity-based PD models remain unknown. α-synuclein hyperphosphorylation is a key event in PD pathogenesis and potential target of therapeutic interventions. We tested whether Ten alleviates α-synuclein-induced cytotoxicity via reducing kinases that phosphorylate α-synuclein.<h4>Meth ...[more]

PMID: 23710708

Similar Datasets

Project description:α-Synuclein is an intrinsically disordered protein that plays a critical role in the pathogenesis of neurodegenerative disorders, such as Parkinson's disease. Proteomics studies of human brain samples have associated the modification of the O-linked N-acetyl-glucosamine (O-GlcNAc) to several synucleinopathies; in particular, the position of the O-GlcNAc can regulate protein aggregation and subsequent cell toxicity. There is a need for site specific O-GlcNAc α-synuclein screening tools to direct better therapeutic strategies. In the present work, for the first time, the potential of fast, high-resolution trapped ion mobility spectrometry (TIMS) preseparation in tandem with mass spectrometry assisted by an electromagnetostatic (EMS) cell, capable of electron capture dissociation (ECD), and ultraviolet photodissociation (213 nm UVPD) is illustrated for the characterization of α-synuclein positional glycoforms: T72, T75, T81, and S87 modified with a single O-GlcNAc. Top-down 213 nm UVPD and ECD MS/MS experiments of the intact proteoforms showed specific product ions for each α-synuclein glycoforms associated with the O-GlcNAc position with a sequence coverage of ∼68 and ∼82%, respectively. TIMS-MS profiles of α-synuclein and the four glycoforms exhibited large structural heterogeneity and signature patterns across the 8+-15+ charge state distribution; however, while the α-synuclein positional glycoforms showed signature mobility profiles, they were only partially separated in the mobility domain. Moreover, a middle-down approach based on the Val40-Phe94 (55 residues) chymotrypsin proteolytic product using tandem TIMS-q-ECD-TOF MS/MS permitted the separation of the parent positional isomeric glycoforms. The ECD fragmentation of the ion mobility and m/z separated isomeric Val40-Phe94 proteolytic peptides with single O-GlcNAc in the T72, T75, T81, and S87 positions provided the O-GlcNAc confirmation and positional assignment with a sequence coverage of ∼80%. This method enables the high-throughput screening of positional glycoforms and further enhances the structural mass spectrometry toolbox with fast, high-resolution mobility separations and 213 nm UVPD and ECD fragmentation capabilities.